Colorectal cancer (CRC) is one of the most common cancer worldwide. However, a large number of genetic risk factors involved in CRC have not been understood. Copy number variations (CNVs) might partly contribute to the 'missing heritability' of CRC. An increased overall burden of CNV has been identified in several complex diseases, whereas the association between the overall CNV burden and CRC risk is largely unknown. We performed a genome-wide investigation of CNVs on genomic DNA from 384 familial CRC cases and 1285 healthy controls by the Affymetrix 6.0 array. An increase of overall CNV burden was observed in familial CRC patients compared with healthy controls, especially for CNVs larger than 50 kb (case/ control ratio = 1.66, P = 0.025). In addition, we discovered for the first time a novel structural variation at 12p12.3 and determined the breakpoints by strategic PCR and sequencing. This 12p12.3 structural variation was found in four of 2862 CRC cases but not in 6243 healthy controls (P = 0.0098). RERGL gene (RERG/ RAS-like), the only gene influenced by the 12p12.3 structural variation, sharing most of the conserved regions with its close family member RERG tumor suppressor gene (RAS-like, estrogen-regulated, growth inhibitor), might be a novel CRC-related gene. In conclusion, this is the first study to reveal the contribution of the overall burden of CNVs to familial CRC risk and identify a novel rare structural variation at 12p12.3 containing RERGL gene to be associated with CRC.
Introduction
Colorectal cancer (CRC) is the third common malignancy and the fourth cause of cancer mortality worldwide, with a similar incidence rate among men and women (1) . The lifetime risk of CRC is about 5% in the general population (2) . As a complex disease, CRC is influenced by genetic and environmental factors, as well as their interactions. According to twin study estimations, heritable factors contribute to about 35% of the CRC risk, whereas the remaining risk is attributed to shared and non-shared environmental factors (3) . A study on the world's biggest Swedish Family Cancer Database showed that the familial risk for CRC are mainly due to heritable causes (4, 5) . Previous studies suggest that CRC displays a high degree of genetic heterogeneity, owing to mutations that inactivate tumor suppressor genes, impair the DNA repair genes or activate oncogenes (6) . Although genes with intermediate-to-high penetrance, such as APC, MLH1, MSH2, TP53, STK11 and SMAD4, have been identified, twothirds of the genetic risk factors of CRC are still unknown (7) .
Recent GWAS have identified several CRC-associated common single nuclear polymorphisms (SNPs) and largely enhanced our understanding of the genetics of CRC in Caucasian population. The variant rs6983267 within the chromosome 8q24 region was the first to be identified in GWAS studies (8, 9) and proved to be involved in Wnt signaling (10) . Additional studies validated other common risk variants, such as rs16892766 on 8q23 (11), rs719725 on 9p24 (9), rs10795668 on 10p14 (11) , rs3802842 on 11q23 (12) , rs4779584 on 15q13 (13) , rs4939827 on 18q21 (12, 14) , rs1321311 on 6q21, rs3824999 on11q13.4, rs5934683 on Xp22.2 (15) . Recent meta-analysis of GWAS also revealed several new loci associated with risk of CRC (16) (17) (18) (19) . However, these identified risk alleles collectively account for only about 7.5% of the familial CRC risk, which suggests that the vast majority of the inherited variations underlying risk of CRC are yet to be discovered (18, 19) . Many explanations for this 'missing heritability' have been suggested, such as rare mutations, DNA copy number variations (CNVs) and epigenetic modifications (20, 21) .
CNVs are structural variants in DNA involving large-scale deletions, duplications and insertions that are typically larger than 1 kb and can be microscopic or submicroscopic (22) . The functional manifestation of CNVs can been varied, from changes in cellular phenotypes, caused by gene expression alternation, to development of complex sporadic or heritable diseases, such as Crohn's disease, obesity, autism, schizophrenia, psoriasis, neuroblastoma, dilated cardiomyopathy, mental retardation and hepatocellular carcinoma (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Yet, the association between CNVs and colorectal cancer has not been systematically investigated. We hereby report the first genome-wide survey of CNVs in the context of familial CRC with the Affymetrix 6.0 array. We analyzed the overall CNV burden in familial CRC cases in comparison with healthy controls and performed further investigation and validation of CRC-associated rare structural variations in a larger sample size.
Materials and methods

Study population
The study protocols were approved by the ethics committee of all participating clinical centers. The GWAS was conducted on a total of 384 unrelated Abbreviations: CNV, copy number variation; CRC, colorectal cancer; GWAS, genome-wide association study; HNPCC, hereditary non-polyposis colorectal cancer; RERGL, RAS-like and estrogen-regulated growth inhibitorlike gene; SNPs, single nuclear polymorphisms.
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index familial CRC cases and 1285 healthy controls. All the CRC cases and controls were Caucasian. The 384 cases comprised of 188 males, 192 females and 4 patients of unknown gender; the mean age was 58.3 years, ranging from 15 to 89 years. All 384 patients had at least one first-degree relative with CRC (71% with one relative, 16% with two relatives, 7% with three or more relatives and 6% with unknown number). Out of the 384 familial CRC cases, 315 were obtained from the regional cancer registry of Schleswig-Holstein base on the following selection criteria: at least two first-degree relatives (including the index patient) affected by CRC in the family (35) . None of the patients or affected relatives from the regional cancer registry of Schleswig-Holstein had clinical signs of familial polyposis coli. The other 69 familial CRC cases were from the German hereditary non-polyposis colorectal cancer (HNPCC) Consortium. The selection criteria for familial CRC of HNPCC were as described previously (36) . All samples from the HNPCC Consortium were confirmed to be microsatellite stable by the Bethesda panel (none of the five markers tested showed instability), indicating absence of germ line mutations in mismatch repair genes (including MLH1, MSH2, MSH3, MSH6 and PMS2) (36, 37) . The 1285 healthy controls free of CRC at the time of recruitment were randomly selected from a population-based control pool of the PopGen project in Schleswig-Holstein (38) . The control group consisted of 711 males and 574 females, with a mean age of 56 years, ranging from 19 to 77 years. A total of 371 CRC cases and 1262 controls were assayed successfully in the discovery phase.
The enlarged sample set included another 2520 CRC cases and 5015 healthy controls. All the CRC cases and controls were Caucasian, which were drawn from two different consortiums. Samples from the cancer registry of Schleswig-Holstein included 2083 CRC cases (1047 males, 1029 females and 7 of unknown gender, with a mean age of 65.2 years, ranging from 17 to 90 years) and 3103 healthy controls (1500 males, 1537 females and 66 of unknown gender, with a mean age of 61.4 years, ranging from 20 to 81 years). Samples from the German HNPCC Consortium included 437 CRC cases (217 males and 218 females, with a mean age of 44 years, ranging from 9 to 82 years) and 1912 healthy controls (957 males and 955 females, with a mean age of 44.4 years, ranging from 18 to 67 years). CRC cases from the HNPCC Consortium were tested to be microsatellite stable, indicating absence of germ line mutations in mismatch repair genes. A total of 2491 cases and 4981 controls were assayed successfully in the enlarged sample set.
Genome-wide association study
Genomic DNA was extracted from peripheral whole blood. All samples for the GWAS (384 familial CRC cases and 1285 controls) were analyzed using the Affymetrix 6.0 array (Affymetrix, Santa Clara, CA) according to the protocol, together with 14 Affymetrix controls. The Affymetrix 6.0 array has 906 600 SNP probes and 940 000 copy number probes. Of these, 800 000 are evenly spaced along the genome, whereas the rest are targeted to 3700 known CNV regions culled from a variety of sources (39) . Thirteen cases and 23 controls failed since they had preliminary Birdseed call rate <95%, or Affymetrix quality control call rate <86%. Thus, a total of 371 cases and 1262 controls were included in the CNV analyses. Primary data analysis was performed with the Affymetrix Genotyping Console software, and the genotype calling was done using the Birdseed 2 algorithm in the Affymetrix Power Tool (APT, http://www. affymetrix.com/partners_programs/programs/developer/tools/powertools. affx). Before analysis, we excluded markers with one or more of the following criteria: <90% genotype call rate (61 152 SNPs), minor allele frequency <5% in cases or controls (224 200 SNPs), or Hardy-Weinberg equilibrium exact P < 0.05 in cases or controls (78 289 SNPs). A total of 352 additional SNPs were rejected after visual quality inspection of the clustering pattern using Affymetrix Genotyping Console (v3.0.2). Finally, 610 664 SNPs passed all quality control filters, with an average call rate of 97.5%. The PLINK software (40) was used to generate complete linkage agglomerative clustering based on pairwise identity-by-state and identity-by-descent. The EIGENSOFT software (41) was used to perform the principal components analysis of the stratification in the genome-wide association studies. The CNVs were estimated with three software programs: APT, Birdsuite (42) and PENNCNV (43) .
Permutation test
To calculate the different overall burden of CNVs in CRC cases and controls, permutation test was performed according to the previous literature (23, 24) with the following steps: (i) The difference in the average CNV burden of cases and controls were calculated. (ii) The case and control samples were pooled. (iii) The difference in the average CNV burden was calculated and recorded for every possible way of dividing these pooled samples into case group and control group randomly. Correspondingly, a set of calculated differences was generated which showed the exact distribution of possible differences under the null hypothesis that was unaffected by the group labels. (iv) The P-value of permutation test was calculated as a proportion of the observed differences in the set of calculated differences. The permutation procedure was conducted in the CRAN R (http://cran.r-project.org/). P-values from one-tailed conditional permutation tests were controlled for differences in total number of CNV calls and data quality in cases and controls.
Identification of rare CNVs in autosomes in cases
The rare autosomal CNVs of cases were filtered out as per the following steps: (i) 227 217 autosomal CNVs (copy number state ≠2) were identified in 371 cases by Birdsuite software version 1.5.5 and the rest were filtered out. (ii) All CNVs with confidence value ≤10 were rejected. A total of 9759 CNVs in 371 cases survived this step. (iii) Single cases with >100 CNVs were rejected as outliers; 6597 CNVs in 366 cases survived this step (five cases were rejected; the remaining 366 cases had an average of 18 CNVs per sample, ranging from 5 to 82 CNVs). (iv) The 6597 CNVs were compared with the human common CNVs map provided by McCarroll et al. (39) . The CNVs that had >50% overlap with the reported common CNVs were rejected as common variants. A total of 4975 CNVs in 366 cases survived this step. (v) The 4975 CNVs identified with Birdsuite software were checked for overlap with the loci data calculated by APT software and PENNCNV software (the same Affymetrix 6.0 array raw data were processed by APT and PENNCNV softwares separately). A total of 4915 CNVs that could not be identified in all three algorithms were rejected. Sixty CNVs in 41 cases survived this step. (vi) All CNVs with size <10 kb were rejected. As a result, five CNVs were rejected, and 55 CNVs in 38 cases survived, whose lengths varied from 11 491 bp to 1 241 067 bp. (vii) One sample was rejected as an outlier because 12 CNVs were found from that sample. A total of 43 CNVs in 37 cases remained with an average of 1.2 CNVs per sample. (viii) The 43 CNVs were cross-referenced to the CNV data analyzed by ATP software. If the sample IDs referred in the overlapping CNV from the Birdsuite software and APT software were not identical, the CNVs were rejected. Thirtyfour CNVs in 30 cases remained. (ix) The 34 CNVs were cross-referenced to the CNV data analyzed by PENNCNV software. All of the 30 CNVs that were >50 kb in length could be found, whereas the four CNVs that were <50 kb had no available data in the PENNCNV and therefore could not be found. (x) The UCSC Genome Browser (http://genome.ucsc.edu) was used to search for the genes located in the 34 CNVs. We only selected the CNVs that contained genes in the CNV region or in the ±50 kb flanking regions for further validation. Furthermore, two CNVs located in the known rearrangement regions were also rejected (23) . As a result, 16 CNVs with lengths from 37 785 bp to 917 026 bp remained for further analysis. (xi) The 16 CNVs were checked in two common CNV databases for healthy Caucasian individuals: the Children's Hospital of Philadelphia (44) database (45) and the CNVs identified by Li et al. (46) . If a CNV had generally >10% overlap or had an overlap in the exon region of genes with the CNVs present in the two databases, this CNV was rejected. Ten CNVs in 10 cases remained for further analysis. (xii) The 10 CNVs were checked in the Birdsuite CNV data of our 1262 controls (confidence values >10). If a CNV identified in the cases had >10% overlap with CNV identified in the controls or had an overlap with the exon regions of genes, the CNV was rejected. Six CNVs in 6 cases were left. (xiii). The 6 CNVs were checked in the Database of Genomic Variants (http://projects.tcag.ca/variation). The CNVs that had >10% overlap with the reported CNVs in the Caucasian controls were rejected. After applying all these selection criteria, only one CNV identified in two patients was left for the further validation.
The data were further interrogated to obtain more information regarding the CNV selected for subsequent validation. In order to check the CNVs that were located in or overlapped with the indentified 12p12.3 94.4 kb deletion in particular, less stringent criteria was applied to filter the Affymetrix SNP 6.0 array data. The CNVs (>1 kb) should have an overlap with the 94.4 kb deletion in cases or controls according to the analyzed data by Birdsuite and PENNCNV softwares irrespective of the confidence value. CNVs identified by both softwares were selected for further verification by strategic PCR and sequencing.
Determination the breakpoint of 94.4 kb deletion by sequencing
The genomic DNA from the three 12p12.3 deletion carriers were used for the verification by PCR and sequencing. PCR primers were designed for the flanking region of this CNV, avoiding repetitive elements. The primer pair yielding successful PCR amplification was forward: 5′-CAAAGCCTGTTAATGAGATTTAGGA-3′ and reverse: 5′-ATTGGT CACAGTCATTATTTGGAGT-3′. The PCR protocol followed the instructions of Expand Long Range, dNTPack (Roche). The 4.5 kb PCR products were treated using the ExoSAP-IT purification kit (GE Healthcare) and sequenced using the reverse primer in a 3130XL Genetic Analyzer (Applied Biosystems). Sequencing results were analyzed using Sequencing Analysis 5.2 software (Applied Biosystems). Although the PCR product was long, the breakpoint was located 283 bp upstream of the reverse primer and therefore could be detected. The same breakpoint was identified in three affected cases.
Genome-wide analysis
Determination of the breakpoint of DNA rearrangement in RERGL promoter region by sequencing Genomic DNA from a carrier of the RERGL promoter structural variation was used for verification by PCR and sequencing. PCR primers were designed for the predicted flanking region of this structural variation avoiding repetitive elements. The primer pair yielding successful PCR amplification is listed as follows: forward: 5′-TACTGCCCCATTACTGTCTT-3′ and reverse: 5′-CATTTGCATTGTTCAGCCTT-3′. The PCR protocol followed the instructions of Hotstar (Qiagen). The 600 bp PCR products were treated using the ExoSAP-IT purification kit (GE Healthcare) and sequenced using the forward and reverse primer via a 3130XL Genetic Analyzer (Applied Biosystems). Sequencing results were analyzed using Sequencing Analysis 5.2 software (Applied Biosystems). The validated breakpoints were very close to the one predicted by the Array data. Thus, the amplification of chromosome 6 segments may be due to the similarity of the sequence and the reverse primer.
TaqMan assay for the identification of the 94.4 kb deletion in large sample size
TaqMan assay was designed for the identified 94.4kb deletion by assigning a probe to the breakpoint and tested in the samples of the enlarged sample set. The sequences of the primers and probe are forward primer: 5′-AAGGCCGGTTTCTCATTATCAGT-3′, reverse primer: 5′-GGGAGGTTTCTTTAATGTGTTTGTTG-3′, and probe: FAM-5′-CTCAG CTAGACACTG-3′. The control primers and probe were designed for the exon5 of RERGL gene: forward primer: 5′-TTGCAAAAGCAAATGAAGACCTAT-3′, reverse primer: 5′-CACTGGGCAGATGGGTTTGT-3′, and probe: VIC-5′-ACTGATGTCATACACAAT-3′. Primers and TaqMan MGB probes were purchased from Applied Biosystems (Foster City, CA). Five to ten nanograms of genomic DNA from peripheral blood were used per assay. The amplification protocol was 50°C for 2 min, 95°C for 10 min, and 45-50 cycles of amplification (92°C, 15 s, and 60°C, 60 s). Samples were analyzed by the Roche LightCycler 480.
Results
We conducted a GWAS of CRC-risk-associated CNVs in the peripheral blood DNA of 384 unrelated German familial CRC index cases and 1285 healthy controls using the Affymetrix Genomewide Human SNP 6.0 array together with 14 Affymetrix controls (Affymetrix, Santa Clara, CA). A total of 371 cases (call rate of 96.6%) and 1262 controls (call rate of 98.2%) passed the quality control and were included in the CNV analysis. We assessed the impact of autosomal structural variations on the risk for familial CRC by two strategies: first, in terms of the alteration of overall CNV burden by comparing familial CRC cases and controls and second, by focusing on rare structural variations that are only detectable in CRC cases.
The association between increased overall CNV burden and familial CRC risk
With the assistance of Birdsuite software, we identified 227 217 autosomal CNVs (copy number state ≠2 in autosomes) in the 371 successfully assayed cases and 764 528 autosomal CNVs in the 1262 successfully assayed controls. Of the CNVs identified by McCarroll et al (39) , who examined CNVs in 270 HapMap samples with the same Affymetrix SNP 6.0 array, 90.8% was found in our healthy controls. To reduce the rate of false-positive CNV identification, we focused upon autosomal CNVs with confidence values >10 and sizes >1 kb in our analyses. Applying these criteria, we observed 9049 CNVs in all the 371 familial CRC cases with size range from 1014 bp to 3 332 589 bp, whereas 21 259 CNVs were found in the 1262 healthy controls with size range from 1020 bp to 21 277 085 bp (only one CNV in controls was >4 Mb, the second largest CNV in controls was 3 523 637 bp). The CNV size distribution was similar in familial CRC cases and healthy controls. The familial CRC cases had an average and median CNV size of 90.9 kb and 40.1 kb, whereas the controls had an average and median CNV size of 85.5 kb and 39.7 kb, respectively. About one-third of the CNVs in familial CRC cases (30%) and controls (35%) were <20 kb, and three quarters of the CNVs in familial CRC cases (73%) and control (75%) were <100 kb in length (Supplementary Figure 1 is available at Carcinogenesis Online).
It has been reported that the overall burden of CNVs in individuals increases in some disorders like schizophrenia, early-onset obesity and Li-Fraumeni syndrome (23, 24, 47) . We therefore investigated the overall burden of CNVs in familial CRC cases compared with controls by one-tailed conditional permutation test (23, 24) . The familial CRC cases had a significantly increased overall burden of CNVs (including deletions and duplications) and deletions compared with controls ( Figure 1A and Table I ). In addition, the overall burden of CNVs and deletions in familial CRC cases compared with controls were significantly higher as size increased, and those >50 kb exerted the highest familial CRC-related risk (one-tailed conditional permutation test, P < 0.05 for all, Figure 1A and Table I ). Our observation was in line with the CNV burden found in schizophrenia and severe early-onset obesity, in which cases have a significantly higher burden of overall CNVs and large deletions but not duplications (23, 24) . We further stratified the analysis of CNV burden by chromosome. Most of the chromosomes showed a size-related relationship between familial CRC risk and overall burden of CNVs, deletions and duplications, with the highest risk exerted by the CNV subgroup >50 kb ( Figure 1B-D , Table I ). Only chromosome 7 exhibited half the duplication burden and an increased deletion burden in familial CRC cases compared with the controls (Figure 1C-D) . It has been reported that monosomy 7 is associated with shorter telomere length and with increased mortality among aplastic anemia patients (48) . In addtion, monosomy 7 is recognized as a characteristic, clonal abnormality associated with acquired myelodysplasia and acute myeloid leukemia (49) . To summarize, our study provides new evidence for the increased burden of structural variation as a genetic risk factor for familial CRC.
Identification of familial CRC-related 12p12.3 rare structural variation
In addition, we searched for CRC-associated rare germline CNVs based on the Affymetrix 6.0 Array. Applying stringent selection criteria (see Materials and methods), we identified a novel deletion of 94.4 kb on chromosome 12p12.3 in two of the 371 index familial CRC cases and none in the matched 1262 healthy controls. The signals of LogR ratio and B-allele frequency observed at 12p12.3 of the two carriers are presented in Figure 2A . The two patients, one male (54 years old, father with CRC) and one female (52 years old, father with CRC), came from unrelated families according to the clinical records and the SNP-array data (Supplementary Figure 2 is available at Carcinogenesis Online). This 94.4 kb deletion was verified by strategic PCR and sequencing in both the affected familial CRC cases and showed identical breakpoints (chr12: 18 115 061-18 209 438; build 36/hg18, Figure 2B ). The 12p12.3 deletion contains only one gene, RERGL. The upstream breakpoint of this 12p12.3 deletion is located in a long terminal repeat element and the downstream of this deletion is located in human chained self alignments ( Figure 2C ). The long terminal repeat elements are often found at breakpoints of both homologous and non-homologous rearrangements (50, 51) . We examined the flanking regions of the breakpoints and identified non-homologous end-joining ( Figure 2D ), which is normally used by cells to repair DNA double-strand breaks (52) . Thus, the 12p12.3 deletion might be linked to DNA repair processes in the germline.
We further had a close look at the Affymetrix SNP 6.0 array data for the CNVs that are located in or overlapped with the 12p12.3 94.4 kb deletion but with less stringent criteria (see Materials and methods). One deletion (predicted at chr12: 18 139 236-18 144 057 build 36/hg18) located at the promoter region of RERGL (chr12: 18 125 070-18 134 381) was found in a 47-year-old female, who has a father with CRC at 57. Another deletion (predicted at chr12: 18135272-18144057) at the promoter region of RERGL was found in a 77-year-old male, who has a brother with CRC at 68. No CNV in or overlapping with the 12p12.3 94.4 kb deletion was found in the 1262 controls even with less stringent criteria. Strategic PCR and sequencing were performed for verification. In the genomic DNA from the 77-year-old male (brother with CRC at 68), a mosaic pattern of intrachromosomal rearrangement in the promoter region of RERGL was observed. We found homologous rearrangements of chromosome 12 and chromosome 6 (breakpoint chr12:18135650/chr6:116214978, build 36/hg18), homologous rearrangements of chromosome 12 and chromosome 3 (breakpoint chr12:18135587/chr3:130508403, build 36/hg18) as well as wild-type chromosome 12 in the germline DNA of this patient (Figure 3 ). However, we could not detect the other breakpoint due to the complex genomic rearrangement and the limited DNA materials. The DNA structural variation in the 47-year-old female has not been verified yet.
Thus, we found three structural variation at 12p12.3 affecting RERGL gene out of 371 familial CRC cases and none in 1262 controls (P = 0.012, two-tailed Fisher's exact test). Unfortunately, due to the lack of DNA materials from familial members of the carriers and the lack of tumor samples, neither familial segregation analysis nor somatic mutation analysis could be performed.
Investigation of the 12p12.3 deletion in a larger sample size
We further investigated the 12p12.3 94.4 kb deletion in the genomic DNA from the enlarged sample set including additional 2520 CRC cases and 5015 healthy controls by TaqMan assay for breakpoint analysis. The specific probe was designed to hybridize across the breakpoint of the 94.4 kb deletion so that only samples with the same breakpoint can be detected. A total of 2491 CRC cases (98.8%) and 4981 healthy controls (99.3%) were successfully assayed by the TaqMan assay. We detected an identical 12p12.3 94.4 kb deletion with the same breakpoints in a 66-year-old unrelated male CRC patient without any known familial history of CRC (Supplementary Figure 3A is available at Carcinogenesis Online). This deletion was further confirmed by PCR and sequencing (Supplementary Figure 3B is available at Carcinogenesis Online). Thus, in our study population, we found DNA structural variation at 12p12.3 in 4 out of 2862 CRC cases (frequency: 1 in 715) but none in 6243 controls (P = 0.0098, two-tailed Fisher's exact test). Moreover, this 12p12.3 structural variation has not been reported in 21 previous genome-wide CNVs studies comprising a total of 4244 Caucasian control individuals (5 studies used the same samples from HapMap Project and the samples were counted only once) (39, 45, 46, (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) .
Discussion
Germline copy number changes responsible for gastrointestinal tract cancers have attracted a lot of attention recently. The copy number changes in genetic gastrointestinal tract cancers such as hereditary diffuse gastric cancer (71) , HNPCC (72) and Familial adenomatous polyposis (73) were widely analyzed by the multiplex ligation dependent probe amplification technique. However, the association of overall burden of CNVs and rare CNVs to the risk of CRC is still largely unknown. In this study, we have performed a genome-wide analysis of CNVs in familial CRC by the Affymetrix Genome-wide Human SNP 6.0 arrays in 384 familial CRC index German cases and 1285 matched healthy controls. Our data have reached sufficient call rate and identified >90% of previously reported CNVs in human genome (39) .
We report here a higher overall burden of CNVs, especially of large CNVs, in the genome of familial CRC patients compared with healthy controls. More specifically, compared with the healthy controls, the familial CRC patients showed higher burden of deletions, especially large deletions, but not duplications. The increase of CNV burden in familial CRC cases can be observed in most of the individual chromosomes. Since the familial CRC samples from the regional cancer registry of Schleswig-Holstein had no clinical signs of familial polyposis coli and also the familial CRC cases from the HNPCC Consortium were microsatellite stable indicating absence of germ line mutations in mismatch repair genes, the increased burden of overall CNVs observed by us should be an independent risk factor for familial CRC. Indeed, we did not investigate the mutations on other familial CRC-related genes, like MUTYH gene. However, given the existence of MUTYH mutation carriers (74,75) in our samples would be very rare, such mutations would occur too rare to impair our claims. We , deletions and duplications in familial CRC cases and controls stratified by chromosome. P-values were derived from one-tailed conditional permutation tests controlled for differences in total number of CNV calls. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 1 × 10 -6
. therefore suggest that to some extent the patients with familial CRC are 'genomic disordered' although we do not know whether the risk of higher overall burden of CNVs is specific for familial CRC or to the CRC in general. The mechanism by which increased CNV burden in genomic DNA influences the risk of CRC in a given person still needs to be resolved. It is still unknown if environmental factors might modify specific CNVs or interact with the overall burden of CNVs and consequently become an etiological component of CRC, particularly of sporadic CRC. Limited by information regarding environmental exposure in our samples, we could not interrogate the interaction of the environmental factors with the CNV burden. An expanded examination of interaction between overall CNV burden and environmental factors should be considered in the future studies. Nevertheless, our study provides a new hint for the etiology of CRC, which is the fragile or disordered genomes, specifically due to the larger structural variations. Our observation of increased overall CNV burden in familial CRC is in line with previous findings in complex disorders like schizophrenia, early-onset obesity and Li-Fraumeni syndrome (23, 24, 47) . However, because of the high cost of the GWAS, we were unable to perform the validation of the CRC-associated increased CNV burden in the enlarged sample set. Confirmation of these findings in other studies and in additional population is warranted. Moreover, we should note that the Affymetrix Genome-wide Human SNP 6.0 array is limited for CNV analysis because of low density of SNP and CNV probe designed on the array and can not cover small-scale CNVs. Even the identified small-scale CNVs may be unreliable because of the low signal quality generated from only a few probes that are undistinguishable from the background noise. To detect small-scale CNVs in the future, the application of next-generation sequencing technique might be helpful. For the first time, we have uncovered an association between a rare 12p12.3 structural variation and CRC risk. This structural variation was found in 4 out of 2862 CRC cases (frequency: 1 in 715) but in none of the 6243 analyzed healthy controls or in the 4244 controls investigated by previous GWAS studies. Three carriers were discovered by the Affymetrix 6.0 Array out of 371 familial CRC cases. Only one carrier was discovered by the TaqMan Assay out of 2491 CRC cases in the enlarged sample set. Since the TaqMan Assay can only detect the CNVs with the identical breakpoints of the 94.4 kb deletion, we speculate the existence of more carriers of the 12p12.3 structural variation in the enlarged sample set, which were undetectable by the TaqMan assay. Thus, the frequency of the 12p12.3 structural variation in the CRC population would be >1 in 715.
Genome-wide analysis
The 12p12.3 structural variation has been observed in families with Meniere's disease, which is characterized by spontaneous attacks of vertigo, fluctuating sensorineural hearing loss, tinnitus and aural fullness (76) . The association between the 12p12.3 structural variation and cancer has not been reported so far. The RERGL gene is the only known gene affected by this structural variation. So far, the function of RERGL is unknown, but protein alignment suggests that RERGL belongs to the Ras superfamily and is very closely related to another family member, the RERG gene (RAS-like, estrogen-regulated, growth inhibitor) encoding a small GTPase (Supplementary Figure 4 is available at Carcinogenesis Online). Being a tumor suppressor, over-expression of RAS-like and estrogen-regulated growth inhibitor protein suppresses cell growth (77) . In addition, the expression of RAS-like and estrogen-regulated growth inhibitor is decreased or lost in breast, kidney, ovary and colon tumor tissues (77, 78) . Moreover, the observation of hypermethylation of RERG in colorectal carcinoma provides further evidence for the tumor suppressor properties of RERG in CRC (79) . Since RERGL shares most of the conserved regions and GTP-binding regions with RERG ( Supplementary  Figure 4 is available at Carcinogenesis Online), and because of the herein observed depletion of RERGL in patients with CRC, we propose that the RERGL gene may function as a tumor suppressor gene. The possibility of tumor related characteristics of RERGL was also highlighted by a very recent report by the Cancer Genome Atlas Network, which found three missense somatic mutations and one synonymous mutation in RERGL gene in the CRC tumor from four unrelated individuals (tumor and paired normal tissue from 224 unrelated CRC cases analyzed by exon sequencing, mutation rate 1/56) (80). Another study also found one missense somatic mutation in RERGL in one CRC case (tumor and paired normal tissue from nine unrelated CRC cases analyzed by whole-genome sequencing, mutation rate 1/9) (81) .
In this study, we have also reported the first complex chromosomal rearrangement or so called chromothripsis in the genomic DNA of a familial CRC patient. The recent study by Kloosterman et al. (82) disclosed chromothripsis as a common somatic genetic variation in primary and metastatic colorectal cancer. Similar chromothripsis of intrachromosomal rearrangements in germline was observed in patients with severe congenital abnormalities and with developmental problems (83, 84) . In addition, the mosaic pattern of genetic variants have also been reported in the genomic DNA and been correlated with cancer (44) . Our discovery of mosaic chromothripsis in the genomic DNA of a familial CRC patient provides further evidence that the fragile or disordered genomes may be a general risk factor for complex inherited diseases.
In conclusion, we performed a genome-wide CNV analysis and validated initially observed CRC-associated rare CNVs in a larger sample size. We conclude that an overall increased burden of CNVs and a rare structural variation at 12p12.3 affecting the RERGL gene are associated with CRC. Further studies are needed to understand the function of RERGL and its contribution to CRC. The cause of the increased burden of CNVs in CRC patients is still unknown. The formation of CNVs is mainly because of the four major mechanisms: non-allelic homologous recombination, non-homologous end-joining, fork stalling and template switching, and L1-mediated retrotransposition (85) . We speculate that the mutations in genes involved in one or more of these pathways may result in the increased burden of CNVs. Further studies are needed to disclose the cause of the CRC-associated increased overall CNV burden.
Supplementary material
Supplementary Figures 1-4 can be found at http://carcin.oxfordjournals.org/
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